Neflamapimod + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dementia With Lewy Bodies

Conditions

Dementia With Lewy Bodies

Trial Timeline

May 1, 2023 → Jun 16, 2025

NCT ID

NCT05869669

About Neflamapimod + Placebo

Neflamapimod + Placebo is a phase 2 stage product being developed by CervoMed for Dementia With Lewy Bodies. The current trial status is completed. This product is registered under clinical trial identifier NCT05869669. Target conditions include Dementia With Lewy Bodies.

What happened to similar drugs?

6 of 20 similar drugs in Dementia With Lewy Bodies were approved

Approved (6) Terminated (1) Active (13)

🔄[18F]NAV4694Navidea BiopharmaceuticalsPhase 3

❌AL001 + Placebo + Open label - AL001AlectorPhase 3

✅E2020 + PlaceboEisaiApproved

🔄ARICEPTEisaiPhase 3

🔄donepezil hclEisaiPhase 3

🔄Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3

✅donepezil hydrochloride (Aricept)EisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07033481	Phase 2	Recruiting	Aug 1, 2025	Oct 1, 2026	Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
NCT06987643	Phase 2	Recruiting	Jun 20, 2025	Jun 28, 2026	Moderate to Severe Acute Ischaemic Stroke
NCT05869669	Phase 2	Completed	May 1, 2023	Jun 16, 2025	Dementia With Lewy Bodies

Competing Products

20 competing products in Dementia With Lewy Bodies

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 3	26
AL001 + Placebo + Open label - AL001	Alector	Phase 3	22
AL001	Alector	Phase 2	25
ATH-1017 + Placebo	LeonaBio	Phase 2	17
IGC AD1 + Placebo	IGC Pharma	Phase 1	19
E2020 + Placebo	Eisai	Approved	43
ARICEPT	Eisai	Phase 3	40
Rasagiline	Eisai	Phase 2	35
Donepezil Hydrochloride	Eisai	Pre-clinical	26
donepezil hcl	Eisai	Phase 3	40
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo	Eisai	Phase 3	40
E2020 + E2020	Eisai	Phase 2	35
donepezil hydrochloride (Aricept)	Eisai	Approved	43
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo	Eisai	Phase 2	35
E2020 + E2020	Eisai	Phase 3	40
Irsenontrine + Placebo	Eisai	Phase 2	35
E2020	Eisai	Phase 2	35
Mecobalamin	Eisai	Approved	43
E2020 + Placebo	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Phase 3	40